Argenx Buys Unnatural Products for Up to $1.15 Billion

Argenx agreed on November 9, 2026, to acquire Unnatural Products, a macrocyclic peptide discovery company based in Santa Cruz, California, in a deal worth up to approximately $1.15 billion. Argenx will pay $550 million in cash upfront and up to $595 million more if specified development and regulatory milestones are hit. Both boards have approved the transaction.

The buyer isn't a stranger. Argenx already holds a minority stake in Unnatural Products, and the two companies have run a multi-target research collaboration since July 2025. That work includes an oral version of the neonatal Fc receptor blocker behind Vyvgart, Argenx's approved antibody treatment, though the acquisition release doesn't name an approved oral replacement and doesn't identify any Unnatural Products candidate in clinical testing.

Unnatural Products was founded in 2016 by Cameron Pye and Joshua Schwochert, who started the company during their doctoral work in Scott Lokey's lab at the University of California, Santa Cruz. It employs more than 50 people. Its specialty is macrocyclic peptides, ring-shaped molecules designed to do work that usually requires an injected antibody, in a form that could be taken by mouth and kept on a shelf.

After the deal closes, the Unnatural Products team and its platform will stay in Santa Cruz as Argenx's dedicated macrocyclic peptide discovery hub. Argenx brings the clinical development and commercial side. Morgan Stanley advised Argenx on the deal, with DLA Piper as its legal adviser, and Latham & Watkins advised Unnatural Products.

The structure tells you where the risk sits. More than half of the headline value, $595 million of the roughly $1.15 billion, is contingent on milestones the release doesn't specify, so the full amount may never be paid. The $550 million upfront, paid from cash on hand, isn't contingent, and it buys a discovery engine rather than a product with sales.

The companies expect the deal to close by the end of 2026, subject to customary closing conditions. Until it does, the acquisition is an agreement, not a completed purchase, and the release doesn't say which programs or events trigger the milestone payments. The next fixed point is the closing itself.

For Argenx, the bet is plain: its antibody business sells injectable immunology treatments, and a working oral peptide platform would let it compete for patients who'd rather take a pill. Whether the Santa Cruz platform produces a clinical asset, and how soon, is the part the announcement can't answer.

Argenx is an immunology company built around antibody engineering, and Vyvgart is its flagship product. A peptide discovery engine sits beside that business rather than inside it: peptides are smaller, they can be designed for oral dosing, and a shelf-stable pill doesn't need the infusion or injection infrastructure an antibody does. That's the capability the $550 million buys access to, if the science holds.